{"name":"Salvat","slug":"salvat","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"G238","genericName":"G238","slug":"g238","indication":"Other","status":"phase_3"},{"name":"DF289","genericName":"DF289","slug":"df289","indication":"Other","status":"phase_3"},{"name":"DF289 plus DF277","genericName":"DF289 plus DF277","slug":"df289-plus-df277","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DF277","genericName":"DF277","slug":"df277","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SVT-15652","genericName":"SVT-15652","slug":"svt-15652","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"}]}],"pipeline":[{"name":"G238","genericName":"G238","slug":"g238","phase":"phase_3","mechanism":"G238 is a small molecule that targets the [unknown] mechanism to treat [unknown] conditions.","indications":[],"catalyst":""},{"name":"DF277","genericName":"DF277","slug":"df277","phase":"phase_3","mechanism":"DF277 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"DF289","genericName":"DF289","slug":"df289","phase":"phase_3","mechanism":"DF289 is a small molecule that targets the [unknown molecular target] to [unknown therapeutic effect].","indications":[],"catalyst":""},{"name":"DF289 plus DF277","genericName":"DF289 plus DF277","slug":"df289-plus-df277","phase":"phase_3","mechanism":"DF289 plus DF277 is a fixed-dose combination targeting multiple pathways in inflammatory or metabolic disease.","indications":[],"catalyst":""},{"name":"SVT-15652","genericName":"SVT-15652","slug":"svt-15652","phase":"phase_3","mechanism":"SVT-15652 is a small molecule that targets the cardiac sodium channel.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPbTQ4dFNtN3ZWMHZHY1NwMmgzbVZvVzF0VElQNWVWWXVHQ1BjTXIxTmQ4VWY4RGdfVlFVYkU0LVBPbHZJQThMQmRHRGFYc19yYXZOeFJVSjh2UFNoR2hfT0tHZmZYdmdpVDJlOWtnQklZSERqdWxidWtvVjJCLWQyMVladEh4b0hsZ0lXZGRkWXFsc1FLU1hjWkdDdmx3WmNSQ0FfT1FGcmIxejI3Rnk3LWpCbm8yNS0xQmUtVFRsajhtTHdrWkZ6S3gwNTNxd1cxTkE3RWZnS2t6V3FLY2FUN2JQbGRrVWlMY1kzRkdRcUVVMms3WUhPQnhCbkwzeWxsRnFva0oyVEVjdUx6ZTAycFBQakh0dXVSRENRb2hfTjBoNEtUOTZGdGtNem5nemJBaEQ0elRhT245eG9H?oc=5","date":"2026-01-28","type":"trial","source":"GlobeNewswire","summary":"Chronic and Acute Pain Clinical Trial Pipeline Analysis: - GlobeNewswire","headline":"Chronic and Acute Pain Clinical Trial Pipeline Analysis:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOX3BGYlhZd2FINXFXOTJtaWl0ajV6RnpkcDBVYnNYbmM3d2VhTjJLQlljS2hCQzZyaC05YlcxaVViMWJOWHdRTlpuaEY3M2xueGNNSXpnZnU4cEhBUHNJNzJEX3E1ZFc1N3BBd0cyVUxFdDZyOWpiOVJ1QVg1aDJ5cVFFYkJBX1BQOVhV?oc=5","date":"2025-10-24","type":"pipeline","source":"Medical Marketing and Media","summary":"Rx Rundown: Alkermes, Takeda, BPD Healthcare and more - Medical Marketing and Media","headline":"Rx Rundown: Alkermes, Takeda, BPD Healthcare and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOdWN2UFlfT3hCVl9pZV9LdWJsT1YtQ091V05UWlJSMjhFYVpNQmpaNk5XNk40aEJFNUxDWkdLeFM5NFVjYmh5UjI4WXNtT1ZYemZxNm42NFpYS1hPTnZITHBsRm5wU1JrYzZtaFhJNVJBZXI0eENvLUt5bXpWMEZ5LWN3SjU3alpKWkU1ZVlCNTVxS0ZVRUpmOEJfRndPMnlZ?oc=5","date":"2025-10-20","type":"regulatory","source":"The Hearing Review","summary":"FDA Approves Clotic for Otomycosis Treatment - The Hearing Review","headline":"FDA Approves Clotic for Otomycosis Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOLU1xYVU1N2Z4R1djUkxJWGFRb2F5bjJ6RzU2NHRkOUY1WWttY0gxTjlEV1dYWmJzb1c3c004ZnpvRkNxOG1KalVoZU94RjBEMzhkWllpQ29xV3FjaW9wSEI4RFlheS00RGhoLS1wcUtJek93UDFlcFozNkJha1o0bk82cGp2U3hRWnl0VQ?oc=5","date":"2022-10-31","type":"regulatory","source":"Contract Pharma","summary":"Salvat Laboratories Submits NDA to FDA - Contract Pharma","headline":"Salvat Laboratories Submits NDA to FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1WVGpVRWJpeEhIY1hPbE9tTnFmZ1VWb3c0b3g4TUMzTTdQNF9idDhkMmlZclBMbnoxY2VidFBNQ1E1d3lLNXJxRlA2TkVxcV9sbFR3WmVlS1hGYm96aDlYeVI3TVY3TUJFUXBkM01KRQ?oc=5","date":"2022-10-21","type":"pipeline","source":"EyeWorld","summary":"EyeWorld Weekly, October 21, 2022 - EyeWorld","headline":"EyeWorld Weekly, October 21, 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxPeVhSd1U3MEdrUk9ZTUlBd2FWYU9ob2xyVmFwdmg2SFhjbGFCd2hWb2xiOEY4NkEteGFuWmp1TWNpUmFKTEoxVVFqWTdlR0hWYlVDU1F3TlVSSVh1OGFjZUd6U3dnQmNtbWRGbkF5QlBsdGc0dXVvZ1FlUUlsMUdkRUFIRWlOLWJKODlyQ0Y5ZGd5MVZrQXpRTXJVQlpUQ2lWX3lXMkl1SDJkUldsVDYtOEZVZ29HcmJlMl8xR3FEeFF4MUVEQ09BSnd6dWpqdm1EX0NZLWlHSDdZRFZ1bUtiUVhDbnV2YWpzak55elloTDcyX0I2RW95U1dJN1JnZWxoX0tGZWhGcG14T3B5SlRiLUhQWFhKdmVMMmIzOTJ0aU5SbVd1a1JFa0JEOA?oc=5","date":"2016-08-31","type":"pipeline","source":"prnewswire.com","summary":"Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution - prnewswire.com","headline":"Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocino","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2007-09-06","type":"pipeline","source":"Business Standard","summary":"Dr Reddy's launches anti-fungal product - Business Standard","headline":"Dr Reddy's launches anti-fungal product","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":5},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}